cIAP1 Ligand-Linker Conjugates 15 are specialized chemical tools designed for targeted protein degradation in the PROTAC (Proteolysis Targeting Chimera) platform. As members of the E3 ligase ligand-linker conjugate category, these molecules feature a cIAP1-binding ligand attached to a versatile linker, making them ideal for constructing bifunctional PROTAC molecules. The cIAP1 (cellular inhibitor of apoptosis protein 1) is an E3 ubiquitin ligase, widely utilized in PROTAC strategies to recruit the ubiquitin-proteasome system for selective protein degradation. Researchers employ cIAP1 ligand-linker conjugates to design and synthesize PROTACs targeting disease-relevant proteins, ultimately enabling innovative therapeutic interventions in oncology, neurodegeneration, and other fields. This conjugate is optimized for chemical stability, high binding affinity to cIAP1, and ease of functionalization, supporting rapid advancement in drug discovery and targeted protein degradation research.
Structure of 1225433-96-4
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
cIAP1 Ligand-Linker Conjugates 15 represent an innovative class of bifunctional molecules designed to enable targeted protein degradation via the ubiquitin-proteasome system. These conjugates integrate a high-affinity ligand specifically for the cellular inhibitor of apoptosis protein 1 (cIAP1), seamlessly connected to a chemically versatile linker, making them essential building blocks for next-generation PROTAC (Proteolysis Targeting Chimera) design and synthesis.
Mechanism
The mechanism of cIAP1 Ligand-Linker Conjugates 15 capitalizes on their ability to hijack the ubiquitin-proteasome pathway. The cIAP1-binding ligand component recruits the endogenous cIAP1 E3 ubiquitin ligase, while the linker facilitates conjugation to a target protein ligand. This architecture brings the E3 ligase into close proximity to the protein of interest, promoting ubiquitination and subsequent proteasomal degradation of the target protein. The result is selective, catalytically driven depletion of pathogenic or unwanted proteins inside cells.
Applications
cIAP1 Ligand-Linker Conjugates 15 serve as foundational elements in the design and synthesis of cIAP1-based PROTACs for research and preclinical drug development. They enable the creation of customized, heterobifunctional molecules targeting a diverse array of disease-relevant proteins, including those implicated in cancer, neurodegeneration, and autoimmune disorders. Additionally, these conjugates are valuable tools for studying E3 ligase biology, validating target degradation in cell-based models, and developing novel therapeutic strategies leveraging targeted protein degradation.
The cIAP1 Ligand-Linker Conjugates 15 serve a pivotal role in PROTACs by facilitating the targeted degradation of proteins through the recruitment of E3 ligases. These conjugates offer significant advantages in selectivity and efficacy, making them invaluable in research applications. The following provides a detailed description of this molecule.
Linker: The linker in this molecule is a medium-length, flexible polyethylene glycol (PEG) chain, providing optimal spacing and solubility. Its cleavability is non-existent, ensuring stability during the degradation process.
Ligand: The ligand is an optimized small-molecule cIAP1 binder, characterized by its high affinity and specificity. Its structural attributes ensure efficient recruitment of the E3 ligase to the target protein.
Reactive Site: The reactive site is an amine-reactive moiety, typically an NHS ester, which efficiently couples with primary amines on the target protein ligand. Recommended reaction types include amide bond formation under mild conditions.
Recommended Target Protein Ligand: The recommended warhead is a small-molecule inhibitor with a reactive amine group, offering precise targeting capabilities. Its advantages include enhanced selectivity and reduced off-target effects, making it ideal for experimental studies in targeted protein degradation. Researchers can explore its application in various cellular contexts to elucidate protein function.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.